慢性骨髄単球性白血病の世界市場:パイプラインインサイト2021

調査会社DelveInsight社が発行したリサーチレポート(データ管理コード:DELV21SE080)
◆英語タイトル:Chronic myelomonocytic leukaemia - Pipeline Insight, 2021
◆発行会社/調査会社:DelveInsight
◆商品コード:DELV21SE080
◆発行日:2021年7月
◆調査対象地域:世界
◆産業分野:グローバル
◆ページ数:60
◆レポート言語:英語
◆レポート形式:PDF
◆納品方式:Eメール(受注後3営業日)
◆販売価格オプション(消費税別)
Single UserUSD2,000 ⇒換算¥228,000見積依頼/購入/質問フォーム
Global Site LicenseUSD6,500 ⇒換算¥741,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらで、ご購入に関する詳細案内はご利用ガイドでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送いたしますので、請求書発行日より2ヶ月以内に銀行振込にて支払をお願いします。(振込先:三菱UFJ銀行/京橋支店/H&Iグローバルリサーチ株式会社)
DelveInsight社の概要及び新刊レポートはこちらでご確認いただけます。

★グローバルリサーチ資料[慢性骨髄単球性白血病の世界市場:パイプラインインサイト2021]についてメールでお問い合わせはこちら
*** レポート概要(サマリー)***

DelveInsight’s, “Chronic myelomonocytic leukaemia – Pipeline Insight, 2021,” report provides comprehensive insights about 25+ companies and 25+ pipeline drugs in Chronic myelomonocytic leukaemia pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Geography Covered
• Global coverage

Chronic myelomonocytic leukaemia Understanding
Chronic myelomonocytic leukaemia: Overview
Chronic myelomonocytic leukaemia (CMML) is a form of leukaemia that is characterised by high numbers of white blood cells, called ‘monocytes’, in the blood and bone marrow. CMML is an uncommon blood cancer with features of two other types of blood cancer. Even though it has leukaemia as part of its name, the World Health Organisation (WHO) classifies CMML as a ‘mixed myelodysplastic (MDS) myeloproliferative neoplasm (MPN)’. MPN is a group of disorders of the bone marrow stem cells that produce excess numbers of one or more types of blood cells (red cells, white cells, or platelets). MDS is a group of diseases that affects, to a greater or lesser extent, the production of normal blood cells in the bone marrow.

Chronic myelomonocytic leukaemia – Pipeline Insight, 2021 report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Chronic myelomonocytic leukaemia pipeline landscape is provided which includes the disease overview and Chronic myelomonocytic leukaemia treatment guidelines. The assessment part of the report embraces, in depth Chronic myelomonocytic leukaemia commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Chronic myelomonocytic leukaemia collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights
• The companies and academics are working to assess challenges and seek opportunities that could influence Chronic myelomonocytic leukaemia R&D. The therapies under development are focused on novel approaches to treat/improve Chronic myelomonocytic leukaemia.

Chronic myelomonocytic leukaemia Emerging Drugs Chapters
This segment of the Chronic myelomonocytic leukaemia report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Chronic myelomonocytic leukaemia Emerging Drugs
• Sabatolimab: Novarits Oncology
Sabatolimab (MBG 453) is an anti T-cell immunoglobulin and mucin domain 3 (anti-TIM3) monoclonal antibody that is being developed by Novartis Oncology. The drug is currently in phase III stage of development for the treatment of Chronic myelomonocytic leukaemia.

• Enasidenib: Servier
Enasidenib (AG 221) is a small molecule, oral inhibitor of isocitrate dehydrogenase 2 (IDH2), being developed by Servier. The drug is currently in phase I stage of development for the treatment of Chronic myelomonocytic leukaemia.
Further product details are provided in the report……..

Chronic myelomonocytic leukaemia: Therapeutic Assessment
This segment of the report provides insights about the different Chronic myelomonocytic leukaemia drugs segregated based on following parameters that define the scope of the report, such as:
• Major Players in Chronic myelomonocytic leukaemia
There are approx. 25+ key companies which are developing the therapies for Chronic myelomonocytic leukaemia. The companies which have their Chronic myelomonocytic leukaemia drug candidates in the most advanced stage, i.e. phase III include, Novarits Oncology.

• Phases
DelveInsight’s report covers around 25+ products under different phases of clinical development like
• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates

• Route of Administration
Chronic myelomonocytic leukaemia pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
• Oral
• Parenteral
• intravitreal
• Subretinal
• Topical.
• Molecule Type

Products have been categorized under various Molecule types such as
• Monoclonal Antibody
• Peptides
• Polymer
• Small molecule
• Gene therapy
• Product Type
Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Chronic myelomonocytic leukaemia: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Chronic myelomonocytic leukaemia therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Chronic myelomonocytic leukaemia drugs.

Chronic myelomonocytic leukaemia Report Insights
• Chronic myelomonocytic leukaemia Pipeline Analysis
• Therapeutic Assessment
• Unmet Needs
• Impact of Drugs

Chronic myelomonocytic leukaemia Report Assessment
• Pipeline Product Profiles
• Therapeutic Assessment
• Pipeline Assessment
• Inactive drugs assessment
• Unmet Needs

Key Questions
Current Treatment Scenario and Emerging Therapies:
• How many companies are developing Chronic myelomonocytic leukaemia drugs?
• How many Chronic myelomonocytic leukaemia drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Chronic myelomonocytic leukaemia?
• What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Chronic myelomonocytic leukaemia therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Chronic myelomonocytic leukaemia and their status?
• What are the key designations that have been granted to the emerging drugs?

Key Players
• Novarits Oncology
• Servier
• Eltrombopag
• Immune-Onc Therapeutics
• H3 Biomedicine
• Chroma Therapeutics
• Nerviano Medical Sciences
• Astex Pharmaceuticals
• Takeda Oncology
• Argenx
• Kura Oncology
• Incyte Corporation
• Genentech, Inc.
• Sensei Biotherapeutics
• Pfizer
• BioLite, Inc.
• Newave Pharmaceutical Inc
• Ellipses Pharma
• Eli Lilly and Company
• Aprea Therapeutics
• Treadwell Therapeutics
• Prelude Therapeutics
• Onconova Therapeutics
• Immune Pharmaceuticals
• Teva Pharmaceutical Industries

Key Products
• Sabatolimab
• Enasidenib
• IO 202
• H3B 8800
• Tefinostat
• NMS 03592088
• Guadecitabine
• Pevonedistat
• Cusatuzumab
• Tipifarnib
• Ruxolitinib
• Venetoclax
• SNS-301
• Cobimetinib
• Glasdegib
• BLEX 404
• LP-108
• Canakinumab
• EP0042
• LY3410738
• APR-246
• CFI-400945
• PRT543
• Rigosertib
• Histamine dihydrochloride injection
• Arsenic trioxide

*** レポート目次(コンテンツ)***

Introduction
Executive Summary
Chronic myelomonocytic leukaemia: Overview
• Causes
• Mechanism of Action
• Signs and Symptoms
• Diagnosis
• Disease Management
Pipeline Therapeutics
• Comparative Analysis
Therapeutic Assessment
• Assessment by Product Type
• Assessment by Stage and Product Type
• Assessment by Route of Administration
• Assessment by Stage and Route of Administration
• Assessment by Molecule Type
• Assessment by Stage and Molecule Type
Late Stage Products (Phase III)
• Comparative Analysis
Sabatolimab: Novartis
• Product Description
• Research and Development
• Product Development Activities
Drug profiles in the detailed report
Mid Stage Products (Phase II)
• Comparative Analysis
Tefinostat: Chroma Therapeutics
• Product Description
• Research and Development
• Product Development Activities
Drug profiles in the detailed report
Early Stage Products (Phase I)
• Comparative Analysis
Enasidenib: Servier
• Product Description
• Research and Development
• Product Development Activities
Drug profiles in the detailed report
Inactive Products
• Comparative Analysis
Chronic myelomonocytic leukaemia Key Companies
Chronic myelomonocytic leukaemia Key Products
Chronic myelomonocytic leukaemia- Unmet Needs
Chronic myelomonocytic leukaemia- Market Drivers and Barriers
Chronic myelomonocytic leukaemia- Future Perspectives and Conclusion
Chronic myelomonocytic leukaemia Analyst Views
Chronic myelomonocytic leukaemia Key Companies
Appendix



*** 免責事項 ***
https://www.globalresearch.co.jp/disclaimer/


※おすすめ調査資料
※当サイト上のレポートデータは弊社H&Iグローバルリサーチ運営のMarketReport.jpサイトと連動しています。
※当市場調査資料(DELV21SE080 )"慢性骨髄単球性白血病の世界市場:パイプラインインサイト2021" (英文:Chronic myelomonocytic leukaemia - Pipeline Insight, 2021)はDelveInsight社が調査・発行しており、H&Iグローバルリサーチが販売します。


◆H&Iグローバルリサーチのお客様(例)◆


※当サイトに掲載していない調査資料も弊社を通してご購入可能ですので、お気軽にご連絡ください。ウェブサイトでは紹介しきれない資料も数多くございます。
※H&Iグローバルリサーチ(登録第5864124号)及びH&I(登録第5783645号)はH&Iグローバルリサーチ株式会社の商標です。